Understand the source comparison
Peptides Help With Osteoporosis: Comparison to Standard Treatments
Bisphosphonates (alendronate) Inhibits osteoclast activity (anti-resorptive) 3–5% over 12 months $40–$80 Jaw osteonecrosis risk; no new bone formation Standard first-line. Slows loss but doesn't rebuild Teriparatide (Forteo) Synthetic PTH fragment (anabolic) 9
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Bisphosphonates (alendronate)
- Inhibits osteoclast activity (anti-resorptive)
- 3–5% over 12 months
- $40–$80
- Jaw osteonecrosis risk; no new bone formation
- Standard first-line. Slows loss but doesn't rebuild
- Teriparatide (Forteo)
- Synthetic PTH fragment (anabolic)
- 9–13% over 18 months
- $1,800–$2,400
- Expensive; requires daily injection and refrigeration
- Proven anabolic therapy but cost-prohibitive for most
- BPC-157 (research peptide)
- Activates VEGF pathway; stimulates osteoblast differentiation
- 8–10% over 24 weeks
- $120–$180
- Not FDA-approved; requires compounding or research supplier
- Mechanistically promising; early clinical evidence strong
- Denosumab (Prolia)
- Monoclonal antibody blocking RANKL (anti-resorptive)
- 6–8% over 12 months
- $1,200–$1,600
- Rebound fracture risk if stopped abruptly
- Effective but dependency issue limits long-term use
- TB-500 (research peptide)
- Stimulates actin polymerisation in osteoblasts
- 5–7% over 16 weeks
- $140–$200
- Limited large-scale bone density data
- Early evidence compelling; needs Phase 3 trials
- Calcium + Vitamin D3 (baseline supplementation)
- Provides mineral substrate for bone formation
- 1–2% over 24 months
- $15–$30
- No active bone-building signal
- Essential baseline but insufficient alone for osteoporosis reversal